Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04112693
Other study ID # RC19_0051
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 21, 2019
Est. completion date November 13, 2023

Study information

Verified date February 2024
Source Nantes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Achalasia is a primary esophageal motility disorder characterized on high-resolution manometry (HRM) studies by 100% failed peristalsis and elevated integrated relaxation pressure of the lower esophageal sphincter. It is further divided into 3 sub-types according to the Chicago classification v3.01. The pathophysiology of achalasia is poorly understood; however, the NGEU is increasingly recognized as playing a key role in the development of this disorder. Similarly, the esophageal muscle tissue is probably involved, but its sampling remained challenging until the recent advent of the POEM procedure. Indeed, it is now possible, easy and safe to take biopsies of the muscle tissue during POEM. Therefore, POEM not only represents an innovative and effective treatment for achalasia, but also an opportunity to better understand its underlying pathophysiological mechanisms. Currently available treatments for achalasia (pneumatic dilation (PD), Heller's myotomy (HM), botox injections, POEM) are "palliative" procedures that do not restore normal contractile function of the esophagus, but a better understanding of the pathophysiological mechanisms underlying this disorder could potentially help developing curative, or even preventative treatments. To date, muscle tissue sampled during a POEM has only been characterized qualitatively (normal, atrophic, hypertrophic) with no assessment of the enteric nervous system. Moreover, there has been no studies of the mucosal or NGEU anomalies on biopsies taken during a minimally invasive procedure for achalasia such as a POEM. This study aims to evaluate the feasibility of the assessment of NGEU and esophageal muscle tissue in biopsies taken during a POEM for achalasia. It also aims to determine whether specific biomarkers within the NGEU and muscle tissue can predict a better therapeutic response to a POEM. The goal is to include 30 patients within 12 months. Given that approximately 100 new cases of achalasia are diagnosed each year at the included centers, and that about 50% of treatment-naive patients are offered and accept to undergo a POEM, recruitment should be completed relatively rapidly. All POEMs will be performed at the CHU de Nantes by a single endoscopist who has already performed more than 100 procedures. Other than the complications related to the POEM itself, the addition of 14 esophageal biopsies required for our study is a very low-risk intervention. Biopsy sampling extends the length of the procedure by only 4-5 minutes and has not been associated with an increased risk of complications in a previous study. Patients will be evaluated at five time points: preinclusion visit (up to four months before the POEM), inclusion visit (day of the POEM), post-POEM phone calls (3-6, 9-12, 22-26 months after POEM). During the preinclusion visit, relevant information regarding inclusion/exclusion criteria, consent, HRM and pH impedance results, past medical history, and pregnancy status (if applicable) will be gathered. At each time point, current medical history, Eckhardt score2 and pH impedance results (if available) will be documented. The patient will also answer the quality of life (SF36)3 and nutritional status questionnaires and will undergo blood sampling for albumin and prealbumin levels. Additionally, on the day of the POEM, there will be another blood sampling for complete blood count, PT, APTT, serum electrolytes and CRP level. Finally, at each post-POEM phone calls, the occurrence of adverse events will be reported. Our primary hypothesis is that the analysis of mucosal and muscle tissue biopsies taken safely during a POEM will allow better characterization of transcriptomic and molecular remodeling of the mucosa (especially the NGEU) and the muscularis propria in achalasia. We also hypothesize that these anomalies could eventually serve as treatment targets and as a way of better stratifying patients according to achalasia type and treatment (in our case, POEM) response.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date November 13, 2023
Est. primary completion date November 13, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female 18 years and above; - Woman of child-bearing age, if using active (oral contraceptive pill, intrauterine device, contraceptive implant) and/or mechanical (condom, diaphragm) contraceptive method; - Treatment-naive (no pneumatic dilation, botox injection, Heller's myotomy) patient with HRM-diagnosed achalasia in whom POEM is indicated; - Thorough oral and written information about the protocol has been provided and patient's consent to participate in the study has been obtained; - The patient is insured under the French social security system. Exclusion Criteria: - Active anticoagulant treatment or coagulation disorder - Past history of achalasia treatment (pneumatic dilation, botox injection, Heller's myotomy) - Pregnancy or breastfeeding - Patient under trusteeship, guardianship, placed under judicial protection, and/or unable to provide consent

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)
In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies intended for histopathological analysis will be analyzed in FFOCT before histopathological analysis. The FFOCT analysis take place for the patient inclued after than 10 november 2020. The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse.

Locations

Country Name City State
France Nantes UH Nantes

Sponsors (5)

Lead Sponsor Collaborator
Nantes University Hospital Hospices Civils de Lyon, LA ROCHE SUR YON HOSPITAL, Rennes University Hospital, University Hospital, Angers

Country where clinical trial is conducted

France, 

References & Publications (3)

Eckardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology. 1992 Dec;103(6):1732-8. doi: 10.1016/0016-5085(92)91428-7. — View Citation

Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, Pandolfino JE; International High Resolution Manometry Working Group. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015 Feb;27(2):160-74. doi — View Citation

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Feasibility of the assessment of Full Field Optical Coherence Tomographie analysis of the mucosa and esophageal muscle percentage of patients for whom FFOCT analysis of the mucosa and esophageal muscle is possible. Day 0
Primary Feasibility of the assessment of the NGEU and esophageal muscle tissue in biopsies taken during a POEM for achalasia. Percentage of patients in whom the molecular and transcriptomic analyses of the NGEU and esophageal muscle tissue are possible Day 0
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Withdrawn NCT02663206 - Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in Spastic Esophageal Disorders N/A
Active, not recruiting NCT00188344 - A Randomized Comparison of Laparoscopic Myotomy and Pneumatic Dilatation for Achalasia N/A
Recruiting NCT04578769 - Assessment of Different Modified POEM for Achalasia N/A
Not yet recruiting NCT05010889 - Quality of Life After POEM for Achalasia
Recruiting NCT02572193 - To Assess the Feasibility of Same Day Discharge Following a POEM Procedure N/A
Terminated NCT02606578 - Achalasia Patient Reported Outcomes
Active, not recruiting NCT01750385 - Bacteremia and Procalcitonin Levels in Peroral Endoscopic Myotomy for Achalasia N/A
Active, not recruiting NCT03404739 - Single- Versus Multiple-dose Antimicrobial Prophylaxis for The Prevention of Infectious Complications Associated With Peroral Endoscopic Myotomy(POEM) for Achalasia Phase 2/Phase 3
Recruiting NCT05602272 - Respiratory and Hemodynamic Implications of Endoscopic Myotomy of the Esophagus and Stomach
Recruiting NCT05113173 - Study on the Relationship Between Pathological Features of Achalasia and Prognosis of Per-oral Endoscopic Myotomy
Completed NCT02999451 - Snare-assisted POEM for Treatment of Esophageal Achalasia N/A
Completed NCT00490750 - Laparoscopic Dor Versus Toupet Fundoplication for the Treatment of Idiopathic Esophageal Achalasia N/A
Recruiting NCT02518542 - Per Oral Endoscopic Myotomy (POEM) and Prolonged Dilatation (PRD) for Achalasia N/A
Recruiting NCT00260585 - Esophageal Cancer Risk Registry
Recruiting NCT05899842 - Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia N/A
Completed NCT03702647 - Ropivacaine For Post-POEM Pain Control N/A
Recruiting NCT01637311 - Peroral Endoscopic Remyotomy for Failed Heller Myotomy N/A
Completed NCT00004416 - Randomized Study of Botulinum Toxin Type A for Achalasia N/A
Not yet recruiting NCT06027190 - Randomized Controlled Study of Optical 3D Navigated Repetitive Transcranial Magnetic Stimulation for Achalasia. N/A